Tzu Chi Medical Journal
Volume 19, Issue 4 , Pages 192-199 , December 2007

Improvement of Cardiac Function in Thalassemia Patients Using Deferiprone

  • Ching-Tien Peng

      Affiliations

    • Department of Laboratory Medicine, China Medical University and China Medical University Hospital, Taichung, Taiwan
    • Department of Pediatrics, China Medical University and China Medical University Hospital, Taichung, Taiwan
    • Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Laboratory Medicine and Pediatrics, China Medical University Hospital, 2, Yuh-Der Road, Taichung, Taiwan
    • ,
  • Chang-Hai Tsai

      Affiliations

    • Department of Pediatrics, China Medical University and China Medical University Hospital, Taichung, Taiwan
    • Department of Biotechnology and Bioinformatics, Asia University, Taichung, Taiwan
    • ,
  • Kang-Hsi Wu

      Affiliations

    • Department of Pediatrics, China Medical University and China Medical University Hospital, Taichung, Taiwan
    • ,
  • Chih-Chao Hsu

      Affiliations

    • Department of Pediatrics, China Medical University and China Medical University Hospital, Taichung, Taiwan
    • ,
  • Tao-Yu Sheng

      Affiliations

    • Department of Pediatrics, China Medical University and China Medical University Hospital, Taichung, Taiwan

Received 28 March 2007 ,Revised 21 May 2007 ,Accepted 25 May 2007.

References 

  1. Zurlo MG , De Stefano P , Borgna-Pignatti C , et al.   Survival and causes of death in thalassaemia major . Lancet . 1989;2:27–30
  2. Modell B , Khan M , Darlison M . Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register . Lancet . 2000;355:2051–2052
  3. Weatherall DJ , Pippard MJ , Callender ST . Editorial retrospective. Iron loading in thalassemia–five years with the pump . N Engl J Med . 1983;308:456–458
  4. Olivieri NF , Brittenham GM , Matsui D , et al.   Iron-chelation therapy with oral deferiprone in patients with thalassemia major . N Engl J Med . 1995;332:918–922
  5. Kontoghiorghes GJ , Bartlett AN , Hoffbrand AV , et al.   Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydrox-ypyrid-4-one (L1). I. Iron chelation and metabolic studies . Br J Haematol . 1990;76:295–300
  6. Agarwal MB , Gupte SS , Viswanathan C , et al.   Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial . Br J Haematol . 1992;82:460–466
  7. Olivieri NF , Brittenham GM , McLaren CE , et al.   Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major . N Engl J Med . 1998;339:417–423
  8. Hoffbrand AV , AL-Refaie F , Davis B , et al.   Long term trial of deferiprone in 51 transfusion dependent iron overloaded patients . Blood . 1998;91:295–300
  9. Anderson LJ , Wonke B , Prescott E , Holden S , Walker JM , Pennell DJ . Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia . Lancet . 2002;360:516–520
  10. Piga A , Gagliotic C , Fogliacco E , Tricta F . Comparative effects of deferioprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis . Haematologica . 2003;88:489–496
  11. Anderson LJ , Holden S , Davis B , et al.   Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload . Eur Heart J . 2001;22:2171–2179
  12. Wu KH , Chang JS , Su BH , Peng CT . Tricuspid regurgitation in patients with beta-thalassemia major . Ann Hematol . 2004;83:779–783
  13. Huang YC , Chang JS , Wu KH , Peng CT . Regression of myocardial dysfunction after switching from deferoxamine to deferiprone in beta-thalassemia major patients . Hemoglobin . 2006;30:229–238
  14. Anderson LJ , Westwood MA , Holden S , et al.   Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance . Br J Haematol . 2004;127:348–355
  15. Borgna-Pignatti C , Rugolotto S , De Stefano P , et al.   Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine . Hematologica . 2004;89:1187–1193
  16. Gabutti V , Piga A . Results of long-term iron-chelating therapy . Acta Haematol . 1996;95:26–36
  17. Telfer PT , Prestcott E , Holden S , Walker M , Hoffbrand AV , Wonke B . Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major . Br J Haematol . 2000;110:971–977
  18. Olivieri NF , Nathan DG , MacMillan JH , et al.   Survival in medically treated patients with homozygous beta-thalassemia . N Engl J Med . 1994;331:574–578
  19. Brittenham GM , Griffith PM , Nienhuis AW , et al.   Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major . N Engl J Med . 1994;331:567–573
  20. Worwood M , Cragg SJ , Jacobs A , McLaren C , Ricketts C , Economidou J . Binding of serum ferritin to concana -valin A: patients with homozygous beta-thalassemia and transfusional iron overload . Br J Haematol . 1980;46:409–416
  21. Wood JC , Tyszka JM , Carson S , Nelson MD , Coates TD . Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease . Blood . 2004;103:1934–1936
  22. Peng CT , Chow KC , Chen JH , Chiang YP , Lin TY , Tsai CH . Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan . Eur J Haematol . 2003;70:392–397
  23. Wu KH , Chang JS , Tsai CH , Peng CT . Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major . Ann Hematol . 2004;83:471–473
  24. Pippard MJ , Callender ST , Warner GT , Warner GT , Weatherall DJ . Iron absorption and loading in beta-thalassemia intermedia . Lancet . 1979;2:819–821
  25. Angelucci E , Brittenham GM , McLaren CE , et al.   Hepatic iron concentration and total body iron stores in thalassemia major . N Engl J Med . 2000;343:327–331
  26. Cohen AR , Galanello R , Pennell DJ , Cunningham MJ , Vichinsky E . Thalassemia . Hematology Am Soc Hematol Educ Program . 2004;14–34
  27. Desferal R Product Monograph. Novartis Inc.
  28. Engle MA , Erlandson M , Smith CH . Late cardiac complications of chronic, severe refractory anemia with hemochromatosis . Circulation . 1964;30:698–705
  29. Davis BA , O'Sullivan C , Jarritt PH , Porter JB . Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major . Blood . 2004;104:263–269
  30. Pennell DJ , Berdoukas V , Karagiorga M , et al.   Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis . Blood . 2006;107:3738–3744
  31. Borgna-Pignatti C , Cappellini MD , De Stefano P , et al.   Cardiac morbidity and mortality deferozamine-or deferiprone-treated patients with thalassemia major . Blood . 2006;107:3733–3737
  32. Peng CT , Wu KH , Wu SF , et al.   Deferiprone or deferoxamine vs. combination therapy in patients with beta-thalassemia major: a case study in Taiwan . Hemoglobin . 2006;30:125–130
  33. Olivieri NF . The beta-thalassemias . N Engl J Med . 1999;341:99–109
  34. Eldor A , Rachmilewitz EA . The hypercoagulable state in thalassemia . Blood . 2002;99:36–43
  35. Aessopos A , Farmakis D , Karagiorga M , et al.   Cardiac involvement in thalassemia intermedia: a multicenter study . Blood . 2001;97:3411–3416
  36. Gladwin MT , Sachdev V , Jison ML , et al.   Pulmonary hyper-tension as a risk factor for death in patients with sickle cell disease . N Engl J Med . 2004;350:886–895
  37. Shalev O , Repka T , Goldfarb A , et al.   Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo . Blood . 1995;86:2008–2013
  38. Abstract Book: 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases, Taichung, Taiwan, April 22–26, 2005.
  39. Peng CT , Fucharoen S , Kontoghiorghes GJ , Tsai CH . Report on the proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases at Taichung, Taiwan, April 22–26, 2005 . Hemoglobin . 2006;30:63–68
  40. Porter JB , Tanner MA , Pennell DJ , Eleftheriou P . Improved myocardial T2* in transfusion dependent anemias receiving ICL670 (deferasirox) . Blood . 2005;106:3600; [ASH Annual Meeting Abstracts]

PII: S1016-3190(10)60016-X

doi: 10.1016/S1016-3190(10)60016-X

Tzu Chi Medical Journal
Volume 19, Issue 4 , Pages 192-199 , December 2007

Article Tools